Market Place
Sourcing Support
Avacta To Present AVA6000 Data At ESMO Congress
08 Sep 2024 //
GLOBENEWSWIRE
Lupin introduces doxorubicin hydrochloride liposome injection in US
29 Aug 2024 //
PHARMABIZ
Enforcement Report - Week of October 25, 2023
25 Oct 2023 //
FDA
Ibrutinib Plus Chemoimmunotherapy Fails to Improve PFS in Pretreated FL, MZL
20 Jun 2023 //
ONCLIVE
LIXTE & Sarcoma Enroll First Patient in Ph 1b/2 Randomized Trial of Doxorubicin
07 Jun 2023 //
GLOBENEWSWIRE
FDA adcomm votes 11-2 to expand Roche`s Polivy label in DLBCL
10 Mar 2023 //
ENDPTS
Seagen Eyes a Key Frontline Indication for Top-Seller Adcetris
13 Dec 2022 //
BIOSPACE
Genentech Presents Data for Polivy at ASH 2022
11 Dec 2022 //
BUSINESSWIRE
Apexigen Announces +ve Interim Results of Ph2 Trial Sotigalimab with Doxorubicin
14 Nov 2022 //
GLOBENEWSWIRE
Celerity`s Generic Doxorubicin Hydrochloride Receives Approval in the U.S.
19 Oct 2022 //
FDA
LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OFA PH1B/2 RANDOMIZED TRIAL DOXORUBICIN
13 Oct 2022 //
GLOBENEWSWIRE
Shasqi Advances SQ3370 to Phase 2 in Solid Tumors
12 Sep 2022 //
PRNEWSWIRE
Biocytogen and Tracon get FDA IND clearance for Phase I/II sarcoma trial
30 Aug 2022 //
CLINICALTRIALSARENA
US FDA Approval of IND for CTLA-4 Antibody YH001
29 Aug 2022 //
BUSINESSWIRE
Genentech lymphoma treatment gets FDA approval
16 Aug 2022 //
LABIOTECH
Avacta`s doxorubicin prodrug clears another early safety test
05 Jul 2022 //
FIERCEPHARMA
Accord Healthcare Zolsketil pegylated liposomal Receives Approval in Europe
20 Jun 2022 //
EMA
EC approves Roche’s Polivy combination in previously untreated diffuse LBCL
26 May 2022 //
EXPRESS PHARMA
ADCETRIS Combination Significantly Improves Overall Survival in Hodgkin Lymphoma
03 Feb 2022 //
BUSINESSWIRE
Data From Pivotal Phase 3 Study of KEYTRUDA + LENVIMA in Endometrial Carcinoma
20 Jan 2022 //
BUSINESSWIRE
ImmixBio IMX-110 Produced 50% Positive Response Rate in First-Line-Therapy
12 Jan 2022 //
GLOBENEWSWIRE
Progression-Free Survival Boost Noted With Polatuzumab Vedotin Plus R-CHP
17 Dec 2021 //
CANCERNETWORK
Seagen Announces Preliminary Results from Phase 2 Trial of ADCETRIS
12 Dec 2021 //
BUSINESSWIRE
Ayana Pharma`s Generic Doxorubicin Hydrochloride Receives Approval In US
15 Oct 2021 //
FDA
Lurbinectedin/Doxorubicin Comparable to Standard of Care for SCLC, But Safer
10 Sep 2021 //
ONCLIVE
Oncopeptides presents new clinical & preclinical melflufen data at EHA meeting
12 May 2021 //
PRNEWSWIRE
Novel ionic liquid enables uniform chemotherapy delivery in solid tumours
15 Feb 2021 //
EUROPEANPHARMACEUTICALREVIEW
Jazz, PharmaMar say confirmatory study of Zepzelca misses main goal
03 Dec 2020 //
PRNEWSWIRE
Enforcement Report - Week of December 2, 2020
02 Dec 2020 //
FDA
Increased Clarity On The Role Of Immunotherapy In Early Tnbc
20 Sep 2020 //
ESMO
Zydus`s Generic Doxorubicin Hydrochloride Receives Approval In US
15 Sep 2020 //
FDA
Zydus Cadila receives US FDA approval for generic Doxil Liposome injection
12 Sep 2020 //
PHARMABIZ
ProtoKinetix AAGP® Moves to Whole Organ Transplantation Testing
14 Aug 2020 //
PROTOK INETIX
European Commission Approves ADCETRIS® (brentuximab vedotin)
14 May 2020 //
BUSINESSWIRE
EMA committee recommends approval of Takeda’s Adcetris in combo
01 Apr 2020 //
PHARMABIZ
Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin)
31 Mar 2020 //
PRESS RELEASE
US FDA approves Noxopharm’s Veyonda in combo with doxorubicin
27 Feb 2020 //
PHARMABIZ
BeyondSpring commences late-stage study of Plinabulin for preventing chemo
23 Oct 2019 //
SEEKINGALPHA
Global Wilms Tumor Pipeline Insight Report 2019 - ResearchAndMarkets.com
21 Oct 2019 //
BUSINESSWIRE
Big Pharma joins £200M UK Biobank sequencing project
12 Sep 2019 //
ENDPOINTS NEWS
Seattle Genetics investors breathe a sigh of relief as Adcetris posts 30% growth
17 Jul 2019 //
FIERCE PHARMA
Monopar, GEIS team up to conduct phase 2 trial of Camsirubicin to treat sarcoma
05 Jul 2019 //
PHARMABIZ
European Commission Approves ADCETRIS® (brentuximab vedotin) with AVD
11 Feb 2019 //
BUSINESSWIRE
Seattle Genetics gets $30 mn for EC Approval of ADCETRIS (Brentuximab Vedotin)
11 Feb 2019 //
BUSINESSWIRE
LARTRUVO (olaratumab) - New clinical trial information important to prescribing decisions
04 Feb 2019 //
HEALTH CANADA
Apexigen Announces Clinical Collaboration Phase 2 Trial For APX005M In Sarcoma
20 Dec 2018 //
PR NEWSWIRE
Merck KGaA Gets Into Deeper Trouble In Immune Checkpoint Inhibition
22 Nov 2018 //
SEEKING ALPHA
PharmaMar to Present Ph I/II Study ResultsWith Lurbinectedin& Doxorubicin
06 Sep 2018 //
PR NEWSWIRE
Keeping Cancer Out of Breath Blocks Drug Resistance
27 Aug 2018 //
R&DMAG
Epizyme Halts Phase II Trial of Tazemetostat in DLBCL
02 Aug 2018 //
GEN
Accord’s biosimilar Pelgraz poised for approval
31 Jul 2018 //
PHARMAPHORUM
AbbVie, J&J’s Imbruvica fails to target in B-Cell lymphoma trial
12 Jul 2018 //
PHARMA TIMES
AbbVie Stock Drops After Disappointing Clinical Trial Update
12 Jul 2018 //
BIOSPACE
Anticancer delivery tech to reduce tissue damage an ‘unexpected surprise’
12 Mar 2018 //
IN PHARMATECHNOLOGIST
Heart group warns of cardiovascular risks after treatment for breast cancer
01 Feb 2018 //
STATNEWS
Enforcement Report - Week of January 31, 2018
31 Jan 2018 //
FDA
